Appili’s management team is comprised of experts in drug development, infectious disease, business development and commercialization, with experience spanning large pharma and emerging biopharmaceutical firms.

KevinS2

Kevin Sullivan, MBA

Chief Executive Officer

Appili CEO Kevin Sullivan has more than 21 years of experience working with early-stage biotechnology companies and has raised over $50 million in private equity and non-dilutive government funding in the space. Before joining Appili, he was CEO at DeNovaMed, Inc., a company focused on Gram-positive and Gram-negative antibiotics, and COO at Viron Therapeutics, which is develops novel immunotherapies. He is also a former diver in the Canadian Navy, and retains a familiarity with and commitment to resolving medical challenges faced by the military.

MT-Stephens

Kimberly Stephens

Chief Financial Officer

Kimberly Stephens, CPA, CA is the Chief Financial Officer, who brings nearly 20 years of financial management experience at public and private companies to her role at Appili.  Most recently CFO of Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF), where she raised more than $40 million in equity financing and government grants, Ms. Stephens began her career as an audit manager at PwC.

Jamie_Image_Bio_MTv3_Test

Jamie Doran MSc, DABT, ERT

Vice President, Drug Development

Jamie Doran, MSc, DABT, ERT, is Vice President, Drug Development at Appili.  She is a board-certified toxicologist with more than16 years of experience in the pharmaceutical, biotechnology, and medical device industries, including overall program management of global drug development programs and product registrations. She has a broad range of experience in evaluating the toxicology and safety of products being registered and used in the global market. Ms. Doran has managed over 100 projects and has been responsible for cross-functional team management and monitoring of multi-million dollar budgets and multi-year programs. Ms. Doran is a Diplomat of the American Board of Toxicology and is as a European Registered Toxicologist with the Institute of Biology & British Toxicology Society (London, United Kingdom).

Sean McBride

Sean McBride

 Vice President, Business Development

Sean McBride serves as Vice President, Business Development at Appili. He has more than 25 years of national and international experience in business development, strategy and marketing for global pharmaceutical companies including GSK, where he led a portfolio of assets valued at $170 million, and Roche, where he served as director of marketing.